Astrazeneca (AZN) EBITDA Margin (2009 - 2026)

Astrazeneca has reported EBITDA Margin for 18 years, with the latest figure at 20.57% in Q2 2026.

• On a quarterly basis, EBITDA Margin fell 371.0% year-over-year to 20.57% in Q2 2026; TTM through Jun 2026 was 22.8%, a 241.0% increase from a year earlier, with the FY2025 full-year figure at 23.44%, up 462.0% from the prior year.
• EBITDA Margin was 20.57% for Q2 2026 at Astrazeneca, down from 27.91% in the prior quarter.
• The five-year high for EBITDA Margin was 27.91% in Q1 2026, with the low at 5.07% in Q2 2022.
• Average EBITDA Margin over 5 years is 19.58%, with a median of 21.33% recorded in 2023.
• The largest YoY upside for EBITDA Margin was 2852 bps in 2022 against a maximum downside of 1840 bps in 2022.
• Over 5 years, EBITDA Margin stood at 23.76% in 2022, then slipped by 10 bps to 21.43% in 2023, then slumped by 33 bps to 14.46% in 2024, then jumped by 33 bps to 19.22% in 2025, then advanced by 7 bps to 20.57% in 2026.
• The last three EBITDA Margin figures came in at 20.57% (Q2 2026), 27.91% (Q1 2026), and 19.22% (Q4 2025), per Business Quant data.